14

Immunology column By Dr. Jo Serrentino

Pre- & post- vaccination with Engystol as adjuvant treatment

About thirty percent of the population suffers from post-vaccinal reactions, which constitutes a serious problem for the medical community, as well as major discomfort for patients. Antihomotoxic preparations can help the practitioner intervene by providing an adjuvant to support the immune system.

Engystol is an immune-modulator, which, according to the Bystander Reaction, seems to prevent the inflammatory response by stimulating macrophages to produce antigen motifs. They in turn activate Th3 regulatory

lymphocytes to bind motifs to their receptors and become Transforming Growth Factor, which mediates Th1 and Th2 lymphocytes and consequently quenches inflammation. In the first quarter of the Nature-Link study (*Biomedical Journal winter 2003*) on immunemodulation using Engystol with or without vaccination (in animals), results warrant the following adjuvant protocol, which may optimize the effect of the vaccine and reduce the chances of post-vaccinal reaction.



PRE-VACCINATION

Adults: 1 vial of Engystol 5 days in a row within 10 days of receiving the vaccination

1 tablet of Engystol t.i.d. for 3 weeks prior to vaccination

Children: 1 drop of Engystol per every year of the child's age, 7 days in a row within 10 days of vaccination

POST-VACCINATION

Adults: Follow vaccination with 1 vial of Engystol 3 x/week for 3 weeks.

1 tablet of Engystol t.i.d. 4-8 weeks, depending on the physician's assessment of how much immune support the patient requires

Children: Follow vaccination with 1 drop of Engystol per every year of the child's age, 3 x/week for 3 weeks

Use a pipette to measure the dosage in drops. Once the oral vial is opened, drain all of its contents into a small pipette and store in a dry place or if no pipette is available, simply cover the vial with a plastic wrap and store in a dry place for a few hours.

